Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11312423 | 1.00 | LMNA (0.33) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL15779345 | 0.71 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL11303738 | 0.70 | — | — | |
| SCHEMBL11303457 | 0.70 | LMNA (0.31) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL15778806 | 0.69 | LMNA (0.37) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL3573704 | 0.64 | — | — | |
| SCHEMBL11361726 | 0.62 | — | — | |
| SCHEMBL21213967 | 0.62 | HSP90AA1 (0.36) | LMNAMAPTTSHRMAPK1RECQL | |
| SCHEMBL16865460 | 0.62 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL17853992 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029139-A1 | COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS | CAAMTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029139-A1 | COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS | HTR1A, HTR2A, HTR1B | LMNA 2379/4885MAPT 1761/4885TSHR 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.